Journey Medical shares are trading lower after the company released topline results from its two Phase 3 trials of DFD-29 for papulopustular rosacea in adults.
Portfolio Pulse from Benzinga Newsdesk
Journey Medical Corporation's shares have dropped following the release of topline results from its two Phase 3 trials of DFD-29 for papulopustular rosacea in adults.
July 11, 2023 | 4:20 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Journey Medical Corporation's stock price is expected to be negatively impacted in the short term due to the release of Phase 3 trial results of DFD-29.
The release of Phase 3 trial results is a significant event for any pharmaceutical company. In this case, the immediate drop in Journey Medical's stock price indicates that the market may have perceived the results as negative. This could lead to a short-term negative impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100